Journal article
Economic Evaluation of Donepezil for the Treatment of Alzheimer's Disease in Canada
Abstract
BACKGROUND: Donepezil is a new drug recently approved in the United States and Canada for the treatment of Alzheimer's disease (AD). We estimated the cost-effectiveness of donepezil 5 mg daily as an adjunct to usual care in the management of persons with mild-to-moderate AD defined as a Mini-Mental Health State Examination (MMSE) score in the range 10 to 26.
METHODS: Treatment effect data as MMSE change-over-baseline scores were obtained from a …
Authors
O'Brien BJ; Goeree R; Hux M; Iskedjian M; Blackhouse G; Gagnon M; Gauthier S
Journal
Journal of the American Geriatrics Society, Vol. 47, No. 5, pp. 570–578
Publisher
Wiley
Publication Date
May 1999
DOI
10.1111/j.1532-5415.1999.tb02572.x
ISSN
0002-8614